Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition
- PMID: 2170513
- DOI: 10.1097/00004872-199008000-00007
Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition
Abstract
The temporal blood pressure course and the diurnal profile of the renin-angiotensin system were examined in 13 patients with essential hypertension receiving hydrochlorothiazide and enalapril once daily. Blood samples were taken and blood pressure was measured before the habitual morning dose of hydrochlorothiazide and enalapril (at 8.00 a.m.) and at seven time points over the next 24 h. During the period of maximal effect of enalapril (from 11.00 a.m. to 2.00 p.m.), the increase in plasma renin concentration ranged from no change to an 800% increase. A negative correlation was observed between an increase in plasma renin and a decrease in immunoreactive plasma angiotensin II concentration (Spearman rank-order correlation coefficient = 0.83). Notably, the greatest changes in plasma renin and angiotensin II concentrations after enalapril were seen in those patients whose blood pressure fell most during the day. We conclude that hypertensive patients on long-term therapy with enalapril once daily vary widely in their between-dose biochemical response to the drug, and that there is a significant association between the responsiveness of the plasma renin-angiotensin system and the effect on 24 h blood pressure.
Similar articles
-
Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-aldosterone system.Hypertension. 1986 Apr;8(4):290-7. doi: 10.1161/01.hyp.8.4.290. Hypertension. 1986. PMID: 3007351
-
Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?Cardiovasc Drugs Ther. 2014 Aug;28(4):335-45. doi: 10.1007/s10557-014-6537-6. Cardiovasc Drugs Ther. 2014. PMID: 24958603 Clinical Trial.
-
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.Circulation. 2003 Oct 14;108(15):1831-8. doi: 10.1161/01.CIR.0000091405.00772.6E. Epub 2003 Sep 29. Circulation. 2003. PMID: 14517164 Clinical Trial.
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
-
Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.J Hypertens Suppl. 1992 Dec;10(7):S157-64. J Hypertens Suppl. 1992. PMID: 1291650 Review.
Cited by
-
ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.J Cereb Blood Flow Metab. 2010 Aug;30(8):1520-6. doi: 10.1038/jcbfm.2010.57. Epub 2010 Apr 21. J Cereb Blood Flow Metab. 2010. PMID: 20407464 Free PMC article.
-
Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.Drugs. 1992 Mar;43(3):346-81. doi: 10.2165/00003495-199243030-00005. Drugs. 1992. PMID: 1374319 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical